GSK’s cancer drug, Jemperli, has been granted priority review by the U.S. Food and Drug Administration (FDA) following promising results from a pivotal trial. The trial demonstrated that a significant proportion of patients with rectal tumors had no detectable signs of cancer for at least one year after treatment.
If approved, the drug could transform the treatment approach for certain rectal cancers, allowing selected patients to potentially avoid chemotherapy, radiation, and surgery. The FDA has set a decision deadline of February 2027, but the application qualifies for accelerated consideration under the National Priority Voucher program, which could lead to an earlier ruling. Additionally, the submission is under review through Project Orbis, opening the possibility of coordinated international approvals.
AZUR-1 Trial Demonstrates No Detectable Cancer After One Year
The FDA’s review is based on the AZUR-1 trial, a global phase II study evaluating Jemperli as a standalone treatment for previously untreated stage II/III locally advanced rectal cancer characterized by dMMR/MSI-H. The primary endpoint was met with clinical complete responses lasting at least 12 months.
The AZUR-1 results showed a substantial improvement compared to the historical standard of care.
The study enrolled 154 patients, each receiving nine cycles of Jemperli over a period of six months. Interim safety findings were consistent with the established profile of the drug.
Possible Shift from Chemoradiation
Traditionally, treatment for this subtype of rectal cancer involves a sequence of chemotherapy, radiation, and surgery. Although effective, this regimen often results in permanent complications.
GSK Senior Vice President Hesham Abdullah commented that traditional treatments, despite being delivered with curative intent, frequently lead to long-term negative impacts on quality of life. Nearly one-third of patients eventually suffer cancer spread to other parts of the body. Jemperli could become the first approved immunotherapy to help some patients delay or eliminate chemotherapy, radiation, and surgery.
Quality-of-Life Stakes
The potential to avoid surgical procedures and their irreversible consequences is significant. Such traditional treatments often result in profound sacrifices in quality of life, including permanent reliance on colostomy bags, physiological dysfunctions, psychological distress, social stigmas, and additional health complications. Possible fertility issues and other debilitating side effects also impact patients’ daily lives.
If Jemperli becomes a first-line treatment option, it could help avoid these outcomes for selected patients.
Tumor Response to Immunotherapy
The AZUR-1 results are supported by earlier findings from Memorial Sloan Kettering Cancer Center, which indicated that PD-1 blockade could produce complete responses without chemoradiation. Tumors with dMMR/MSI-H exhibit numerous genetic changes, making them more visible to the immune system, which attracts a greater number of immune cells.
Anti-PD-1 immunotherapies like Jemperli enhance the immune system’s ability to attack cancer cells.
Identifying tumors through biomarker testing is crucial, although it does not guarantee a response for every patient.
Regulatory and Next Steps
The FDA has set a PDUFA date for February 2027, but expedited review under the National Priority Voucher program could mean an earlier decision. The application is also part of Project Orbis, allowing simultaneous international evaluations.
The combination of priority review and other designations highlights the urgency of delivering new treatment options for patients with limited alternatives. If approved, Jemperli would be the first immunotherapy capable of potentially eliminating or delaying traditional treatments for some rectal cancer patients.
Clinicians will need to incorporate biomarker testing and consider immunotherapy-first strategies in their diagnostic processes.
Milestone for GSK’s Oncology Program
GSK’s oncology portfolio has expanded, with Jemperli being fundamental to its immuno-oncology strategy. GSK’s shares have risen, reflecting investor confidence. The AZUR-1 milestone is crucial for bringing scientific innovation to patients.
GSK is advancing Phase 3 trials in gastrointestinal cancers to address longstanding care gaps. Detailed interim results from AZUR-1 will be presented later this year to inform global regulatory submissions.
GSK remains focused on ongoing Phase 3 trials in gastrointestinal cancer, where patient need and advances in biology are presenting new opportunities.
Leave a Reply